Director/PDMR Shareholding

RNS Number : 8353U

Oncimmune Holdings PLC

27 October 2017

 

27 October 2017

Oncimmune Holdings plc

("Oncimmune" or the "Company")

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR AND PERSONS CLOSELY ASSOCIATED WITH THEM

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that on 25 October 2017, share options over 420,000 £0.01 ordinary shares of the Company were awarded to staff and directors (who are PDMRs) under the Company's 2016 Share Option Plan (an amalgamation of the Company's 2005 and 2007 Share Option Plans) as follows.

Name	Position	Number of Share Options Awarded	Exercise price per Share	Percentage of issued ordinary share capital
Meinhard Schmidt	Non-executive Chairman	300,000	£1.215	0.552%
Andrew Millet	Chief Financial Officer	30,000	£1.215	0.055%
Other employees (not directors or PDMR's)		90,000	£1.215	0.165%

The options are subject to the rules of the 2016 Share Option Plan and vest in five equal annual parts, the first fifth vesting on 27 October 2018 and each year thereafter for a further four years, subject to continued employment. Unless otherwise indicated in the table above, the options are exercisable at 121.5 pence, being the mid-market price of the Company's ordinary shares at the close of day on 25 October 2017

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Broker)

Giles Balleny

[phone]

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

[e-mail]

[phone]

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Meinhard Schmidt
2	Reason for the notification
a)	Position/status	Non-Executive Chairman, Director
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oncimmune Holdings plc
b)	LEI	213800HCYIWT6YPI1I02
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	options over 1p ordinary shares - 2016 Share Option Plan ISIN GB00BYQ94H38
b)	Nature of the transaction	Grant of options over ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) N/A 300,000
d)	Aggregated information	Price(s) Volume(s) N/A 300,000
e)	Date of the transaction	25 October 2016
f)	Place of the transaction	N/A

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Andrew Millet
2	Reason for the notification
a)	Position/status	Chief Financial Officer, Director
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oncimmune Holdings Plc
b)	LEI	213800HCYIWT6YPI1I02
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	options over 1p ordinary shares  - 2016 Share Option Plan ISIN GB00BYQ94H38
b)	Nature of the transaction	Grant of options over ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) N/A 30,000
d)	Aggregated information	Price(s) Volume(s)         N/A             30,000
e)	Date of the transaction	25 October 2017
f)	Place of the transaction	N/A

 

END

 

 

DSHGCBDGGXDBGRR